| Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (NCT05315258) | University of Oxford | 2022-07-25 |
| Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma (NCT05986331) | Biocad | 2022-07-18 |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (NCT05432193) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2022-07-13 |
| Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma (NCT05307289) | Centre Hospitalier Universitaire de Nice | 2022-05-25 |
| Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms (NCT05402046) | MelanomaPRO, Russia | 2022-04-23 |
| Zr89 + PET Companion Trial (NCT05279027) | Abramson Cancer Center at Penn Medicine | 2022-03-08 |
| Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (NCT05402059) | MelanomaPRO, Russia | 2022-03-02 |
| MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] (NCT06299878) | Russian Academy of Medical Sciences | 2022-01-01 |
| App Teaches Doctors to Diagnose Skin Cancer (NCT05661370) | Herlev Hospital | 2021-11-15 |
| Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (NCT04901988) | The Christie NHS Foundation Trust | 2021-11-08 |
| MoleGazer Development Feasibility Study (NCT05015816) | Oxford University Hospitals NHS Trust | 2021-09-13 |
| Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo (NCT04969419) | Momentum Data | 2021-06-18 |
| Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (NCT04990479) | Nouscom SRL | 2021-06-11 |
| This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. (NCT05061940) | Repertoire Immune Medicines | 2021-05-05 |
| OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women (NCT04834167) | Universiti Tunku Abdul Rahman | 2021-05-01 |
| Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (NCT04904120) | Perspective Therapeutics | 2021-03-05 |
| To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment (NCT04821570) | University of Kansas Medical Center | 2021-02-23 |
| A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (NCT04911998) | Pierre Fabre Medicament | 2021-02-02 |
| Melanoma Detection in Switzerland With VECTRA (NCT04605822) | University Hospital, Basel, Switzerland | 2021-01-25 |
| Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm (NCT04695015) | Peking University | 2020-12-31 |
| AI-based Medical Device Validation for Early Melanoma Detection (NCT06221397) | AI Labs Group S.L | 2020-09-17 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (NCT04410445) | Nektar Therapeutics | 2020-07-27 |
| Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors (NCT03927742) | University of Minnesota | 2020-06-09 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma (NCT04072900) | Xiangya Hospital of Central South University | 2020-04-21 |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) (NCT04353050) | Russian Academy of Medical Sciences | 2020-04-01 |
| Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors (NCT03518229) | University of Minnesota | 2020-02-01 |
| Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 (NCT03233828) | Carman Giacomantonio | 2019-10-30 |
| A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer (NCT04099446) | ProgenaBiome | 2019-10-01 |
| Passive Versus Active Educational Interventions for Melanoma Recognition (NCT04507048) | Azienda USL Reggio Emilia - IRCCS | 2019-09-01 |
| SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) (NCT04079166) | Scancell Ltd | 2019-08-19 |
| Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (NCT03949153) | University Hospital, Strasbourg, France | 2019-08-16 |
| Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma (NCT04066725) | University of Utah | 2019-07-25 |
| Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage (NCT04688749) | Aristotle University Of Thessaloniki | 2019-07-17 |
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma (NCT03972046) | TriHealth Inc. | 2019-06-24 |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma (NCT04337931) | Apexigen America, Inc. | 2019-06-12 |
| Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits (NCT04550000) | DermTech | 2019-03-01 |
| Biobanking and New Biomolecular Metrics (NCT05906277) | Regina Elena Cancer Institute | 2019-01-29 |
| Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. (NCT03581188) | University of Sydney | 2018-11-01 |
| Elucid Labs AIDA™ - Labelled Image Acquisition Protocol (NCT03621462) | Elucid Labs Inc. | 2018-10-15 |
| Pembrolizumab and EDP1503 in Advanced Melanoma (NCT03595683) | University of Chicago | 2018-10-02 |
| Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (NCT03620019) | UNC Lineberger Comprehensive Cancer Center | 2018-09-10 |
| Identification of Metabolic Phenotypes Associated With Melanoma Metastasis (NCT06400550) | University of Texas Southwestern Medical Center | 2018-08-01 |
| Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (NCT03543969) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-14 |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (NCT03224208) | Fondazione Melanoma Onlus | 2018-05-17 |
| Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma (NCT03416933) | Institut de Cancérologie de Lorraine | 2018-04-27 |
| New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy (NCT03136783) | Centre Hospitalier Universitaire, Amiens | 2018-04-05 |
| Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics (NCT03643289) | East and North Hertfordshire NHS Trust | 2018-04-04 |
| Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) (NCT03535077) | Orlucent, Inc | 2018-01-24 |
| Nevus Doctor Clinical Decision Support for GPs (NCT03246412) | University Hospital of North Norway | 2018-01-17 |
| Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery (NCT03405155) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-01-17 |
| Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery (NCT02997553) | Institut de Cancérologie de Lorraine | 2017-11-29 |
| SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer (NCT03294330) | Milton S. Hershey Medical Center | 2017-10-11 |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (NCT03291002) | CureVac | 2017-09-25 |
| A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients (NCT04200040) | OrienGene Biotechnology Ltd. | 2017-08-27 |
| Reflectance Confocal Microscopy to Diagnose MM & LM (NCT03508297) | Skin Care Network Ltd. | 2017-03-14 |
| Melanoma Patients Immunized with Natural DenDritic Cells (NCT02993315) | Radboud University Medical Center | 2016-10-01 |
| Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma (NCT04062032) | University of Utah | 2016-09-27 |
| Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma (NCT02652455) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-08 |
| Skin Health Online for Melanoma: Better Risk Assessment (NCT03130569) | University of New Mexico | 2015-08-26 |
| Using MC1R Genotype to Impact Melanoma Risk Behavior (NCT03509467) | H. Lee Moffitt Cancer Center and Research Institute | 2015-08-03 |
| Genomic Investigation of Unusual Responders (NCT03740503) | University Health Network, Toronto | 2013-11-01 |
| Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim (NCT01489423) | Eastern Cooperative Oncology Group | 2013-04-26 |
| Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers (NCT01477463) | Stanford University | 2012-09-01 |
| French Clinical Datbase of Melanoma Patients (RIC-Mel) (NCT03315468) | Nantes University Hospital | 2012-03-01 |
| Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate (NCT01209299) | ECOG-ACRIN Cancer Research Group | 2012-01-19 |
| Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim (NCT01388569) | Eastern Cooperative Oncology Group | 2011-06-28 |
| Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690 (NCT00937781) | ECOG-ACRIN Cancer Research Group | 2011-02-08 |
| Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery (NCT00962845) | Rutgers, The State University of New Jersey | 2010-09-01 |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (NCT01176474) | H. Lee Moffitt Cancer Center and Research Institute | 2010-08-13 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 (NCT01176461) | H. Lee Moffitt Cancer Center and Research Institute | 2010-08-04 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma (NCT00976573) | Alliance for Clinical Trials in Oncology | 2010-04-01 |
| Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery (NCT00700882) | Eastern Cooperative Oncology Group | 2009-07-02 |
| Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma (NCT00991991) | Case Comprehensive Cancer Center | 2009-07-01 |
| Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma (NCT01005537) | Fred Hutchinson Cancer Center | 2009-06-01 |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00866840) | Rutgers, The State University of New Jersey | 2009-04-01 |
| Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma (NCT00863330) | Wake Forest University Health Sciences | 2009-02-01 |
| Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured (NCT00798629) | H. Lee Moffitt Cancer Center and Research Institute | 2008-11-01 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00471471) | Ahmad Tarhini | 2008-10-01 |
| Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery (NCT00626405) | Alliance for Clinical Trials in Oncology | 2008-08-01 |
| 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma (NCT00729807) | University of Maryland, Baltimore | 2008-07-01 |
| Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer (NCT00704938) | National Institutes of Health Clinical Center (CC) | 2008-06-01 |
| Vaccine Therapy in Treating Patients With Advanced Melanoma (NCT00705640) | Craig L Slingluff, Jr | 2008-05-01 |
| Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma (NCT00658892) | Mayo Clinic | 2008-04-08 |
| A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma (NCT00661336) | Duke University | 2008-04-01 |
| Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases (NCT00540969) | Alliance for Clinical Trials in Oncology | 2008-02-01 |
| Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom (NCT00757614) | Cancer Research UK | 2008-02-01 |
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy (NCT00897520) | ECOG-ACRIN Cancer Research Group | 2008-01-14 |
| Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery (NCT00521001) | Alliance for Clinical Trials in Oncology | 2008-01-01 |
| Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma (NCT00514085) | NCIC Clinical Trials Group | 2007-12-13 |
| Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma (NCT00672321) | Leeds Cancer Centre at St. James's University Hospital | 2007-12-01 |
| Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00568048) | Swiss Cancer Institute | 2007-12-01 |
| Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma (NCT00617799) | University of Nebraska | 2007-10-02 |
| Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain (NCT00550654) | National Institutes of Health Clinical Center (CC) | 2007-10-01 |
| Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer (NCT00553683) | Rutgers, The State University of New Jersey | 2007-10-01 |
| Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg (NCT00565968) | Duke University | 2007-10-01 |
| Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma (NCT00755976) | Cancer Trials Ireland | 2007-08-01 |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma (NCT00512889) | Dana-Farber Cancer Institute | 2007-08-01 |
| BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (NCT00526149) | European Organisation for Research and Treatment of Cancer - EORTC | 2007-07-01 |
| Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma (NCT00897546) | ECOG-ACRIN Cancer Research Group | 2007-06-01 |